Abstract
Psychological maturation continues into young adulthood when substance abuse and several psychiatric disorders often emerge. Marijuana is the most common illicit drug abused by youths, typically preceding other illicit substances. We aimed to evaluate the complex and poorly studied relationships between marijuana use, psychiatric symptoms, and cortisol levels in young marijuana users. Psychiatric symptoms and salivary cortisol were measured in 122 youths (13–23 years old) with and without marijuana use. Psychiatric symptoms were evaluated using the Symptom-Checklist-90-R and Brief Psychiatric Rating Scale. Mid-day salivary cortisol levels were measured. Additionally, salivary cytokine levels were measured in a subset of participants. Although the cortisol levels and salivary cytokine levels were similar, the young marijuana users had more self-reported and clinician rated psychiatric symptoms than controls, especially anxiety-associated symptoms. Moreover, marijuana users with earlier age of first use had more symptoms, while those with longer abstinence had fewer symptoms. Greater cumulative lifetime marijuana use was also associated with greater psychiatric symptoms. The discordant anxiety (feeling stressed or anxious despite normal cortisol) in the marijuana users, as well as symptom exacerbations with early and continued marijuana use in young marijuana users suggest that marijuana use may contribute to an aberrant relationship between stress response and psychiatric symptoms. The greater symptomatology, especially in those with earlier initiation and greater marijuana usage, emphasize the need to intervene for substance use and perceived anxiety in this population.
Similar content being viewed by others
References
ABCD (2014) Adolescent brain cognitive development study. (NIAAA, NIDA, & NCI): U.S. DHHS. http://addictionresearch.nih.gov/adolescent-brain-cognitive-development-study
Adam EK (2006) Transactions among adolescent trait and state emotion and diurnal and momentary cortisol activity in naturalistic settings. Psychoneuroendocrinology 31:664–679
Armario A (2010) Activation of the hypothalamic-pituitary-adrenal axis by addictive drugs: different pathways, common outcome. Trends Pharmacol Sci 31:318–325
Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE (2002) Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 325:1212–1213
Berdyshev EV, Boichot E, Germain N, Allain N, Anger JP, Lagente V (1997) Influence of fatty acid ethanolamides and delta9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells. Eur J Pharmacol 330:231–240
Block RI, Farinpour R, Schlechte JA (1991) Effects of chronic marijuana use on testosterone, luteinizing hormone, follicle stimulating hormone, prolactin and cortisol in men and women. Drug Alcohol Depend 28:121–128
Caballero A, Tseng KY (2012) Association of Cannabis Use during Adolescence, Prefrontal CB1 Receptor Signaling, and Schizophrenia. Front Pharmacol 3:101
Cabral GA (2006) Drugs of abuse, immune modulation, and AIDS. J Neuroimmune Pharmacol 1:280–295
Chang L, Yakupov R, Cloak C, Ernst T (2006) Marijuana use is associated with a reorganized visual-attention network and cerebellar hypoactivation. Brain 129:1096–1112
Cloak CC, Alicata D, Chang L, Andrews-Shigaki B, Ernst T (2011) Age and sex effects levels of choline compounds in the anterior cingulate cortex of adolescent methamphetamine users. Drug Alcohol Depend 119:207–215
Degenhardt L, Hall W, Lynskey M (2003) Exploring the association between cannabis use and depression. Addiction 98:1493–1504
DeSantis AS, DiezRoux AV, Hajat A, Aiello AE, Golden SH, Jenny NS, Seeman TE, Shea S (2012) Associations of salivary cortisol levels with inflammatory markers: the Multi-Ethnic Study of Atherosclerosis. Psychoneuroendocrinology 37:1009–1018
Fergusson DM, Horwood LJ (2000) Does cannabis use encourage other forms of illicit drug use? Addiction 95:505–520
Fokos S, Panagis G (2010) Effects of delta9-tetrahydrocannabinol on reward and anxiety in rats exposed to chronic unpredictable stress. J Psychopharmacol 24:767–777
Freeman D, McManus S, Brugha T, Meltzer H, Jenkins R, Bebbington P (2011) Concomitants of paranoia in the general population. Psychol Med 41:923–936
Fride E (2004) The endocannabinoid-CB receptor system: Importance for development and in pediatric disease. Neuro Endocrinol Lett 25:24–30
Friedman H, Eisenstein TK (2004) Neurological basis of drug dependence and its effects on the immune system. J Neuroimmunol 147:106–108
Giedd J (2004) Structural Magnetic Resonance Imaging of the Adolescent Brain. Ann N Y Acad Sci 1021:77–85
Huizink AC, Ferdinand RF, Ormel J, Verhulst FC (2006) Hypothalamic-pituitary-adrenal axis activity and early onset of cannabis use. Addiction 101:1581–1588
Jaspan HB, Lawn SD, Safrit JT, Bekker LG (2006) The maturing immune system: implications for development and testing HIV-1 vaccines for children and adolescents. AIDS 20:483–494
Johns LC, Cannon M, Singleton N, Murray RM, Farrell M, Brugha T, Bebbington P, Jenkins R, Meltzer H (2004) Prevalence and correlates of self-reported psychotic symptoms in the British population. Br J Psychiatry 185:298–305
Johnston LD, O’Maley PM, Bachman JG, Schulenberg JE (2012) Monitoring the Future national survey results on drug use, 1975–2011. In. Ann Arbor: Institute for Social Research, University of Michigan
Kessler DA, Natanblut SL, Wilkenfeld JP, Lorraine CC, Mayl SL, Bernstein IB, Thompson L (1997) Nicotine addiction: a pediatric disease. J Pediatr 130:518–524
King G, Alicata D, Cloak C, Chang L (2010) Psychiatric symptoms and HPA axis function in adolescent methamphetamine users. J Neuroimmune Pharmacol 5:582–591
King GR, Ernst T, Deng W, Stenger A, Gonzales RM, Nakama H, Chang L (2011) Altered brain activation during visuomotor integration in chronic active cannabis users: relationship to cortisol levels. J Neurosci 31:17923–17931
Klein TW, Newton C, Larsen K, Lu L, Perkins I, Nong L, Friedman H (2003) The cannabinoid system and immune modulation. J Leukoc Biol 74:486–496
Koshibu K, Levitt P, Ahrens ET (2004) Sex-specific, postpuberty changes in mouse brain structures revealed by three-dimensional magnetic resonance microscopy. Neuroimage 22:1636–1645
Lai HM, Sitharthan T (2012) Exploration of the comorbidity of cannabis use disorders and mental health disorders among inpatients presenting to all hospitals in New South Wales, Australia. Am J Drug Alcohol Abuse 38:567–574
Marinelli M, Piazza PV (2002) Interaction between glucocorticoid hormones, stress and psychostimulant drugs. Eur J Neurosci 16:387–394
Monea A, Gruber R, Elod N, Beresescu G, Moldovn C, Monea M (2014) Saliva and serum levels of TNF-alpha and IL-6 in a sample of Romanian adult subjects with Type 2 diabetes mellitus and periodontal disease. Eur Sci J 10:350–359
Moretti S, Castelli M, Franchi S, Raggi MA, Mercolini L, Protti M, Somaini L, Panerai AE, Sacerdote P (2014) Delta(9)-Tetrahydrocannabinol-induced anti-inflammatory responses in adolescent mice switch to proinflammatory in adulthood. J Leukoc Biol 96:523–534
Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M (2009) Cannabinoids as novel anti-inflammatory drugs. Future Med Chem 1:1333–1349
O’Donovan A, Hughes BM, Slavich GM, Lynch L, Cronin MT, O’Farrelly C, Malone KM (2010) Clinical anxiety, cortisol and interleukin-6: evidence for specificity in emotion-biology relationships. Brain Behav Immun 24:1074–1077
Paus T, Keshavan M, Giedd JN (2008) Why do many psychiatric disorders emerge during adolescence? Nat Rev Neurosci 9:947–957
Romeo RD (2010) Pubertal maturation and programming of hypothalamic-pituitary-adrenal reactivity. Front Neuroendocrinol 31:232–240
Romeo RD, Sisk CL (2001) Pubertal and seasonal plasticity in the amygdala. Brain Res 889:71–77
SAMHSA (2009) Results from the 2008 National survey on drug use and health: national findings. HHS, Rockville
Sinha R (2008) Chronic stress, drug use, and vulnerability to addiction. Ann N Y Acad Sci 1141:105–130
Sjogren E, Leanderson P, Kristenson M, Ernerudh J (2006) Interleukin-6 levels in relation to psychosocial factors: studies on serum, saliva, and in vitro production by blood mononuclear cells. Brain Behav Immun 20:270–278
Steiner MA, Wotjak CT (2008) Role of the endocannabinoid system in regulation of the hypothalamic-pituitary-adrenocortical axis. Prog Brain Res 170:397–432
Tournier M, Sorbara F, Gindre C, Swendsen JD, Verdoux H (2003) Cannabis use and anxiety in daily life: a naturalistic investigation in a non-clinical population. Psychiatry Res 118:1–8
Upadhyaya HP, Deas D, Brady KT, Kruesi M (2002) Cigarette smoking and psychiatric comorbidity in children and adolescents. J Am Acad Child Adolesc Psychiatry 41:1294–1305
van Leeuwen AP, Creemers HE, Greaves-Lord K, Verhulst FC, Ormel J, Huizink AC (2011) Hypothalamic-pituitary-adrenal axis reactivity to social stress and adolescent cannabis use: the TRAILS study. Addiction 106:1484–1492
Ventura J, Nuechterlein KH, Subotnik KL, Gutkind D, Gilbert EA (2000) Symptom dimensions in recent-onset schizophrenia and mania: a principal components analysis of the 24-item Brief Psychiatric Rating Scale. Psychiatry Res 97:129–135
Williamson S, Munro C, Pickler R, Grap MJ, Elswick RK Jr (2012) Comparison of biomarkers in blood and saliva in healthy adults. Nurs Res Pract 2012:246178
Acknowledgments
We are grateful to those who participated in this study. We also thank I. Chin MD and R Gonzales MS for coordinating participant visits and sample analyses, G King PhD for manuscript feedback, and C. Jiang MS for statistical consultation.
Grant Support
This study is jointly supported by the National Institutes of Health (NIH), Bethesda, MD): National Institute of Neurological Disorders and Stroke (2U54 NS039406 (to DA); U54 NS56883 (to L Chang)), National Institute on Drug Abuse (1 K24-DA016170 (to L Chang), K01-DA021203 (to C Cloak)), National Center for Research Resources (G12RR003061 & P20RR11091 (to T Ernst)), the Queen Emma Research Fund (to C Cloak) and the Hawaii Community Foundation Victoria S and Bradley L Geist Foundation (to C Cloak).
Disclosures
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this paper.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cloak, C.C., Alicata, D., Ernst, T.M. et al. Psychiatric Symptoms, Salivary Cortisol and Cytokine Levels in Young Marijuana Users. J Neuroimmune Pharmacol 10, 380–390 (2015). https://doi.org/10.1007/s11481-015-9606-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11481-015-9606-0